Turnstone Biologics Corp. Common Stock (TSBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has a cash flow conversion efficiency ratio of -0.292x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.30 Million) by net assets ($14.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Turnstone Biologics Corp. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Turnstone Biologics Corp. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Turnstone Biologics Corp. Common Stock (TSBX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Turnstone Biologics Corp. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ceres Power Holdings PLC
LSE:CWR
|
0.024x |
|
Scandinavian ChemoTech AB Series B
ST:CMOTEC-B
|
-0.698x |
|
Banaras Beads Limited
NSE:BANARBEADS
|
-0.026x |
|
Oxford BioMedica PLC
LSE:OXB
|
0.072x |
|
Raytech Holding Limited Ordinary Shares
NASDAQ:RAY
|
0.013x |
|
Phoenix New Media Limited
NYSE:FENG
|
-0.002x |
|
Workspace Group PLC
LSE:WKP
|
0.018x |
|
Northann Corp.
NYSE MKT:NCL
|
-0.204x |
Annual Cash Flow Conversion Efficiency for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Turnstone Biologics Corp. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see TSBX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.47 Million | $-67.44 Million | -2.143x | -219.65% |
| 2023-12-31 | $98.67 Million | $-66.15 Million | -0.670x | -195.73% |
| 2022-12-31 | $-101.47 Million | $-71.06 Million | 0.700x | +25.63% |
| 2021-12-31 | $-81.85 Million | $-45.63 Million | 0.557x | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.